The Anglo-Swedish pharmaceutical giant AstraZeneca faces mounting pressure from shareholders regarding ongoing investigations in China, one of its key markets. The concerns emerged after the detention of Leon Wang, the company’s China head and executive vice president of international business, by Chinese authorities on 31 October 2023.
The uncertainty surrounding Wang’s detention has created unease among Nordic investors, with AstraZeneca shareholder Lucy Coutts from investment firm JM Finn describing the situation as having “blindsided the company.”
The pharmaceutical company’s challenges in China expanded beyond Wang’s case. More than 100 former sales staff in China received jail sentences in a significant medical insurance fraud case. Additionally, a third investigation emerged in November involving two current and two former senior executives, concerning the import of AstraZeneca cancer drugs from Hong Kong.
China represents a crucial market for AstraZeneca, contributing 13% of total sales in 2023. The company had announced plans to build a $450 million factory in China and had established several licensing agreements with Chinese companies during the same year.
In response to these developments, AstraZeneca appointed Iskra Reic as the new executive vice president for international, based in Shanghai, replacing Wang in December. However, investors have expressed concerns about appointing an executive without Mandarin language skills or previous experience living in China to manage such a complex market during this sensitive period.
Market Recovery and Future Outlook
Despite initial market turbulence that saw approximately $18 billion wiped from AstraZeneca’s value, shares have shown resilience with a 2% increase since early November. Chief Financial Officer Aradhana Sarin has acknowledged potential revenue impacts on the China business extending into 2025.
Financial analysts at Barclays suggest AstraZeneca might face a penalty to resolve the Wang investigation, drawing parallels to British drugmaker GSK’s 2014 case in China, which resulted in a fine of nearly 300 million pounds.
Source: Reuters
